RecruitingNCT05518617

Molecular and Functional Imaging in Monogenic PD.

Molecular and Functional Imaging of Parkinson's Pathology in SNCA, Parkin and PINK1 Mutation Carriers

Sponsor

University of Exeter

Enrollment

45 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Parkinson Disease Neurodegenerative Diseases Nervous System Disorder Neurodegenerative Disease, Hereditary Parkinson's

Summary

In this study, the investigators aim to find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of PD symptoms.

Eligibility

Min Age: 25 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is using specialized brain scans (PET and other imaging) to understand how genetic mutations in the LRRK2 and GBA genes affect brain function in people who carry these mutations — whether or not they have Parkinson's disease yet. This helps researchers understand early disease changes. **You may be eligible if...** - You are 25 years or older - You carry a genetic mutation linked to Parkinson's disease (such as LRRK2 or GBA) OR you have a confirmed Parkinson's diagnosis - Women must not be pregnant or breastfeeding, and those of childbearing age must use effective contraception - You are able to travel to the research site and follow study procedures **You may NOT be eligible if...** - You are under 25 - You are pregnant or breastfeeding - You are unwilling or unable to use contraception - You cannot travel to the research site or comply with the study protocol Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPositron Emission Tomography (PET) scan using DASB tracer

DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons. The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data. To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,